CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 609094-609273 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T71490","span":{"begin":0,"end":179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The mean change in PIQoL-AD score from baseline to week 24 was -3.3 in the pimecrolimus group vs. -2.6 in the CS-based treatment group (37.6% vs. 26.8% improvement, respectively)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T213","span":{"begin":0,"end":179},"obj":"Sentence"}],"text":"The mean change in PIQoL-AD score from baseline to week 24 was -3.3 in the pimecrolimus group vs. -2.6 in the CS-based treatment group (37.6% vs. 26.8% improvement, respectively)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5727","span":{"begin":25,"end":27},"obj":"Disease"},{"id":"T5729","span":{"begin":59,"end":62},"obj":"Disease"}],"attributes":[{"id":"A5727","pred":"mondo_id","subj":"T5727","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A5728","pred":"mondo_id","subj":"T5727","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A5729","pred":"mondo_id","subj":"T5729","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"}],"text":"The mean change in PIQoL-AD score from baseline to week 24 was -3.3 in the pimecrolimus group vs. -2.6 in the CS-based treatment group (37.6% vs. 26.8% improvement, respectively)."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T3052","span":{"begin":25,"end":27},"obj":"Phenotype"}],"attributes":[{"id":"A3052","pred":"hp_id","subj":"T3052","obj":"http://purl.obolibrary.org/obo/HP_0001047"}],"text":"The mean change in PIQoL-AD score from baseline to week 24 was -3.3 in the pimecrolimus group vs. -2.6 in the CS-based treatment group (37.6% vs. 26.8% improvement, respectively)."}